Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

SM. Ansell, PJ. Bröckelmann, G. von Keudell, HJ. Lee, A. Santoro, PL. Zinzani, GP. Collins, JB. Cohen, JP. de Boer, J. Kuruvilla, KJ. Savage, M. Trněný, M. Provencio, U. Jäger, W. Willenbacher, R. Wen, A. Akyol, J. Mikita-Geoffroy, MA. Shipp, A....

. 2023 ; 7 (20) : 6266-6274. [pub] 20231024

Language English Country United States

Document type Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc24007903

Grant support
P30 CA008748 NCI NIH HHS - United States

Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) for whom autologous hematopoietic cell transplantation (auto-HCT) had failed experienced frequent and durable responses to nivolumab in the phase 2 CheckMate 205 trial. We present updated results (median follow-up, ∼5 years). Patients with R/R cHL who were brentuximab vedotin (BV)-naive (cohort A), received BV after auto-HCT (cohort B), or received BV before and/or after auto-HCT (cohort C) were administered with nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity. Patients in cohort C with complete remission (CR) for 1 year could discontinue nivolumab and resume upon relapse. Among 243 patients (cohort A, n = 63; B, n = 80; and C, n = 100), the objective response rate (ORR) was 71.2% (95% confidence interval [CI], 65.1-76.8); the CR rate was 21.4% (95% CI, 16.4-27.1). Median duration of response, CR, and partial remission were 18.2 (95% CI, 14.7-26.1), 30.3, and 13.5 months, respectively. Median progression-free survival was 15.1 months (95% CI, 11.3-18.5). Median overall survival (OS) was not reached; OS at 5 years was 71.4% (95% CI, 64.8-77.1). In cohort C, all 3 patients who discontinued in CR and were subsequently re-treated achieved objective response. No new or unexpected safety signals were identified. This 5-year follow-up of CheckMate 205 demonstrated favorable OS and confirmed efficacy and safety of nivolumab in R/R cHL after auto-HCT failure. Results suggest patients may discontinue treatment after persistent CR and reinitiate upon progression. This trial was registered at www.clinicaltrials.gov as #NCT02181713.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007903
003      
CZ-PrNML
005      
20240423160355.0
007      
ta
008      
240412s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2023010334 $2 doi
035    __
$a (PubMed)37530622
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ansell, Stephen M $u Mayo Clinic, Rochester, MN
245    10
$a Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study / $c SM. Ansell, PJ. Bröckelmann, G. von Keudell, HJ. Lee, A. Santoro, PL. Zinzani, GP. Collins, JB. Cohen, JP. de Boer, J. Kuruvilla, KJ. Savage, M. Trněný, M. Provencio, U. Jäger, W. Willenbacher, R. Wen, A. Akyol, J. Mikita-Geoffroy, MA. Shipp, A. Engert, P. Armand
520    9_
$a Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) for whom autologous hematopoietic cell transplantation (auto-HCT) had failed experienced frequent and durable responses to nivolumab in the phase 2 CheckMate 205 trial. We present updated results (median follow-up, ∼5 years). Patients with R/R cHL who were brentuximab vedotin (BV)-naive (cohort A), received BV after auto-HCT (cohort B), or received BV before and/or after auto-HCT (cohort C) were administered with nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity. Patients in cohort C with complete remission (CR) for 1 year could discontinue nivolumab and resume upon relapse. Among 243 patients (cohort A, n = 63; B, n = 80; and C, n = 100), the objective response rate (ORR) was 71.2% (95% confidence interval [CI], 65.1-76.8); the CR rate was 21.4% (95% CI, 16.4-27.1). Median duration of response, CR, and partial remission were 18.2 (95% CI, 14.7-26.1), 30.3, and 13.5 months, respectively. Median progression-free survival was 15.1 months (95% CI, 11.3-18.5). Median overall survival (OS) was not reached; OS at 5 years was 71.4% (95% CI, 64.8-77.1). In cohort C, all 3 patients who discontinued in CR and were subsequently re-treated achieved objective response. No new or unexpected safety signals were identified. This 5-year follow-up of CheckMate 205 demonstrated favorable OS and confirmed efficacy and safety of nivolumab in R/R cHL after auto-HCT failure. Results suggest patients may discontinue treatment after persistent CR and reinitiate upon progression. This trial was registered at www.clinicaltrials.gov as #NCT02181713.
650    _2
$a lidé $7 D006801
650    _2
$a nivolumab $x terapeutické užití $7 D000077594
650    12
$a Hodgkinova nemoc $x patologie $7 D006689
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a brentuximab vedotin $7 D000079963
650    12
$a imunokonjugáty $7 D018796
650    _2
$a chronická nemoc $7 D002908
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bröckelmann, Paul J $u University of Cologne, Cologne, Germany and Center for Integrated Oncology Aachen Bonn Duesseldorf, Bonn, Germany
700    1_
$a von Keudell, Gottfried $u Memorial Sloan Kettering Cancer Center, New York, NY
700    1_
$a Lee, Hun Ju $u University of Texas MD Anderson Cancer Center, Houston, TX $1 https://orcid.org/0000000172195562
700    1_
$a Santoro, Armando $u Humanitas University, Pieve Emanuele, Milan, Italy and IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano, Milan, Italy $1 https://orcid.org/0000000317099492
700    1_
$a Zinzani, Pier Luigi $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Instituto di Ematologia "Seràgnoli" and Università di Bologna, Bologna, Italy $1 https://orcid.org/0000000221122651 $7 xx0314852
700    1_
$a Collins, Graham P $u Churchill Hospital, Oxford, United Kingdom
700    1_
$a Cohen, Jonathon B $u Winship Cancer Institute, Atlanta, GA $1 https://orcid.org/0000000227236481
700    1_
$a de Boer, Jan Paul $u Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
700    1_
$a Kuruvilla, John $u Princess Margaret Cancer Centre, Toronto, ON, Canada
700    1_
$a Savage, Kerry J $u BC Cancer, Vancouver, BC, Canada $1 https://orcid.org/0000000258359863
700    1_
$a Trněný, Marek $u Charles University in Prague, Prague, Czech Republic
700    1_
$a Provencio, Mariano $u University Hospital Puerta de Hierro, Majadahonda, Spain
700    1_
$a Jäger, Ulrich $u Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000198261062
700    1_
$a Willenbacher, Wolfgang $u Innsbruck Medical University and Sydena GmbH, Connect to Cure, Innsbruck, Austria $1 https://orcid.org/0000000177021721
700    1_
$a Wen, Rachael $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Akyol, Alev $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Mikita-Geoffroy, Joanna $u Bristol Myers Squibb, Boudry, Switzerland
700    1_
$a Shipp, Margaret A $u Dana-Farber Cancer Institute, Boston, MA $1 https://orcid.org/0000000239496897
700    1_
$a Engert, Andreas $u University of Cologne, Cologne, Germany and Center for Integrated Oncology Aachen Bonn Duesseldorf, Bonn, Germany
700    1_
$a Armand, Philippe $u Dana-Farber Cancer Institute, Boston, MA
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 7, č. 20 (2023), s. 6266-6274
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37530622 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160351 $b ABA008
999    __
$a ok $b bmc $g 2081733 $s 1217670
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 7 $c 20 $d 6266-6274 $e 20231024 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
GRA    __
$a P30 CA008748 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options